Author: Brian Casey

RSNA Goes All-In on AI

Posted on by Brian Casey

CHICAGO – It’s been AI all the time this week at RSNA 2024. From clinical sessions packed with the latest findings on AI’s utility to technical exhibits crowded with AI vendors, artificial intelligence and its impact on radiology was easily the hottest trend at McCormick Place.

Radiology greeted AI with initial skepticism when the first applications like IBM Watson were introduced at RSNA around a decade ago.

  • But the field’s attitude has been evolving to the point where AI is now being viewed as perhaps the only technology that can save the discipline from the vicious cycle of rising exam volume, falling reimbursement, and pervasive levels of burnout.

RSNA telegraphed the shift last year by announcing that Stanford University’s Curtis Langlotz, MD, PhD, would be RSNA 2024 president. 

  • Langlotz is one of the most respected AI researchers and educators in radiology, and even coined the phrase that while AI would not replace radiologists, radiologists with AI would replace those without it. 

In his president’s address, Langlotz echoed this theme, painting a picture of a future radiology in which humans and machines collaborate to deliver better patient care than either could alone.

  • Langlotz’s talk was followed by a presentation by another prominent AI luminary – Nina Kottler, MD, of Radiology Partners.

Kottler took on the concerns that many in radiology (and in the world at large) have about AI as a disruptive force in a field that cherishes its traditions.

  • She advised radiology to take a leading role in AI adoption, repeating a famous quote that the best way to predict the future is to create it yourself. 

What were the other trends besides AI at RSNA 2024? They included…

  • Photon-counting CT, which is likely to see new market entrants in 2025.
  • Total-body PET, with PET scanners that have extra-long detector arrays.
  • Theranostics, a discipline that integrates diagnosis and therapy and promises to breathe new life into SPECT.
  • CT colonography and CCTA, which will see positive reimbursement changes in 2025.
  • Continued growth of CT lung screening, especially as a tool for opportunistic screening of other conditions.
  • Continued expansion of AI for breast screening.

The Takeaway

The RSNA meeting has been called radiology’s Super Bowl and World Cup all rolled into one, and this year didn’t disappoint. RSNA 2024 showed that radiology is prepared to fully embrace AI – and a future in which humans and machines collaborate to deliver better patient care.

Mammo AI Kicks Off RSNA 2024

Posted on by Brian Casey

Welcome to RSNA 2024! This year’s meeting is starting with a bang, with two important sessions highlighting the key role AI can play in breast screening. 

Sunday’s presentations cap a year that’s seen the publication of several large studies demonstrating that AI can improve breast cancer screening while potentially reducing radiologist workload. 

  • That momentum is continuing at RSNA 2024, with morning and afternoon sessions on Sunday dedicated to mammography AI. 

Some findings from yesterday’s morning session include … 

  • Two AI algorithms were better than one when supporting radiologists in breast screening, with cancer detection ratios relative to historic performance rising from 0.97 to 1.08 with one AI to 1.09 to 1.14 with two algorithms.
  • ScreenPoint Medical’s Transpara algorithm was able to prioritize the worklist for 57% of breast screening exams by assigning risk scores to mammograms, helping reduce report turnaround times. 
  • iCAD’s ProFound AI software helped radiologists detect 7.8% more breast cancers on DBT exams, and cancers were detected at an earlier stage. 
  • Applying AI for breast screening to a racially diverse population yielded evenly distributed performance improvements.

Meanwhile, the Sunday afternoon session also included significant mammography AI presentations, such as …

  • A hybrid screening strategy – with suspicious breast cancer cases only recalled if the AI exhibits high certainty – reduced workload 50%. 
  • Lunit’s Insight DBT AI showed potential to reduce interval cancer rates in DBT screening by identifying 27% of false-negative and 36% of interval cancers.
  • In the ScreenTrustCAD trial in Sweden, using Lunit’s Insight MMG algorithm to replace a double-reading radiologist reduced workload 50% with comparable cancer detection rates.
  • A German screening program found that ScreenPoint Medical’s Transpara AI boosted the cancer detection rate by 8.7% (from 0.68% to 0.74%), with 8.8% of cancers solely detected by AI.
  • Researchers took a look back at abnormality scores from three commercially available AI algorithms after cancer diagnosis, finding evidence that cancers could be detected earlier. 

The Takeaway

Breast screening seems to be the clinical use case where radiologists need the most help, and Sunday’s sessions show the progress AI is making toward achieving that reality. 

Be sure to check back on our X, LinkedIn, and YouTube pages for more coverage of this week’s events in Chicago. And if you see us on the floor of McCormick Place, stop and say hello!

How Should AI Be Monitored?

Posted on by Brian Casey

Once an AI algorithm has been approved and moves into clinical use, how should its performance be monitored? This question was top of mind at last week’s meeting of the FDA’s new Digital Health Advisory Committee.

AI has the potential to radically reshape healthcare and help clinicians manage more patients with fewer staff and other resources. 

  • But AI also represents a regulatory challenge because it’s constantly learning, such that after a few years an AI algorithm might be operating much differently from the version first approved by the FDA – especially with generative AI. 

This conundrum was a point of discussion at last week’s DHAC meeting, which was called specifically to focus on regulation of generative AI, and could result in new rules covering all AI algorithms. (An executive summary that outlines the FDA’s thinking is available for download.)

Radiology was well-represented at DHAC, understandable given it has the lion’s share of authorized algorithms (73% of 950 devices at last count). 

  • A half-dozen radiology AI experts gave presentations over two days, including Parminder Bhatia of GE HealthCare; Nina Kottler, MD, of Radiology Partners; Pranav Rajpurkar, PhD, of Harvard; and Keith Dreyer, DO, PhD, and Bernardo Bizzo, MD, PhD, both of Mass General Brigham and the ACR’s Data Science Institute.  

Dreyer and Bizzo directly addressed the question of post-market AI surveillance, discussing ongoing efforts to track AI performance, including … 

The Takeaway

Last week’s DHAC meeting offers a fascinating glimpse at the issues the FDA is wrestling with as it contemplates stronger regulation of generative AI. Fortunately, radiology has blazed a trail in setting up structures like ARCH-AI and Assess-AI to monitor AI performance, and the FDA is likely to follow the specialty’s lead as it develops a regulatory framework.

Non-Physicians Are Reading More Medical Images

Posted on by Brian Casey

Non-physician practitioners are reading more medical images in U.S. medical offices. That’s according to a new study in JACR by researchers who found that the share of images interpreted by NPPs has doubled in the last 10 years. 

In the U.S., radiologists consider themselves to be the primary interpreters of medical images, but inroads have been made not only by other physicians but also by non-physician practitioners like nurses and physician assistants. 

  • NPPs are supposed to receive specialized training in image interpretation, but radiologists question whether such training is adequate, especially compared to the years of training that radiologists receive. 

Previous research has documented the rise in NPP image interpretation, but the new study takes a longer view, examining the period 2013-2022. 

  • It also specifically focuses on the medical office setting, where it’s believed NPP interpretation is growing faster than in hospitals, where radiologists still dominate interpretations. 

In their analysis of Medicare claims, researchers from the ACR’s Harvey L. Neiman Health Policy Institute found … 

  • NPPs’ share of office-based image interpretations grew 9% annually (2.5% to 5.5%).
  • Growth rates varied by modality, with MRI growing at 9.9% annually, followed by CT (9.4%), ultrasound (9.4%), radiography (8.9%), and nuclear medicine (7.2%).
  • Despite the growth, just 5.6% of NPPs were interpreting images.
  • By specialty, the share of NPP interpretation was most common with primary care (40%) and orthopedic offices (34%).

The researchers also tracked variability in NPP interpretation rates by state, finding the highest rates ( ~13%) in Western states with large rural areas like Montana, Alaska, and Idaho, where presumably there are fewer radiologists available to read images. 

The Takeaway

The findings provide a good news/bad news look at non-physician image interpretation. The good news for radiologists is that NPP interpretation is still pretty rare; the bad news is that rates are growing quickly. And given the ongoing radiologist shortage, there is sure to be continuing pressure to allow allied health staff to read images on their own.

Will Congress Stop Medicare Cuts?

Posted on by Brian Casey

Radiologists find themselves once again in a familiar position, facing CMS cuts in Medicare and Medicaid physician payments for 2025. A new analysis by revenue cycle management company Healthcare Administrative Partners details the impact of the reductions, as well as other reimbursement changes set to take effect next year. 

CMS has been driving down radiology reimbursement for years, a trend widely seen as part of the agency’s effort to shift funding from medical specialties to primary care. 

  • That’s having an impact on physician pay, as a study last week found that private-practice diagnostic radiologists have seen inflation-adjusted salaries decline at a -1% annual rate since 2014. 

That trend is set to continue in 2025, with CMS publishing its final rule for the Medicare Physician Fee Schedule that affirms most of the changes it proposed in July. In the new article, HAP’s Sandy Coffta unpacks the changes, which include … 

  • A new conversion factor of $32.3465 (down from $33.2875).
  • Payment reductions of -2.8% for radiology and nuclear medicine, and -4.8% for interventional radiology.

But not all of the changes are negative. Other 2025 policies that affect radiology include …

  • Reimbursement for CT colonography for Medicare beneficiaries at a rate of $108.68 for the professional component.
  • New codes for reporting MRI safety procedures.
  • New quality category measures in the Merit-based Incentive Payment System.

CMS proposed similar cuts last year, but Congress swooped in at the last minute to roll them back with the Consolidated Appropriations Act, which applied a positive 2.93% upward adjustment. 

  • Several bills in Congress now would likewise stave off the 2025 reductions (H.R. 2474 and H.R. 10073), but time is running out to pass them before the current Congressional session expires on January 3, 2025. 

The Takeaway

Will Congress once again ride to the rescue and stave off Medicare reimbursement cuts, as it did a year ago? Or will things be different this time, given the political turbulence that’s shaking Washington, DC? We’ll find out in a few weeks.

Radiologist Salaries Lag Inflation

Posted on by Brian Casey

A new study in JACR confirms what many radiologists have suspected: salary growth for private-practice radiologists has lagged inflation over the last 10 years. While there were a few bright spots, the study mostly shows that radiologists are working harder for less pay. 

Radiology has long been one of the better-compensated medical specialties, often landing in the top 10 of disciplines with the highest average annual compensation. 

  • But radiology has also been a target for reimbursement cuts by the U.S. government as it tries to shift more Medicare and Medicaid payments to primary care practitioners.

As a result, previous studies have found that payments per Medicare beneficiary in radiology have actually declined. 

  • And another 2.83% cut is on the docket for 2025 unless Congress steps in before the end of the current legislative session to prevent cuts in the 2025 Medicare Physician Fee Schedule.

The new study analyzes radiologist compensation based on MGMA salary survey data from 2014 to 2023. 

  • Researchers compared salaries for both diagnostic and interventional radiologists, and also between private-practice and academic radiologists. 

Based on the data, they found …

  • Diagnostic radiologists saw median total compensation grow over the survey period, but at a faster rate for academic radiologists (32% vs. 18%). 
  • Academic radiologists enjoyed faster annualized salary growth (3.2% vs. 1.9%) and had an edge after adjustment for inflation (+0.3% vs. -1%).
  • Work RVUs (a measure of productivity) also grew but at a slightly higher rate for academic radiologists (21% vs. 20%). 
  • Interventional radiologists saw higher salary growth for both non-academic and academic physicians (41% and 35%). 

The findings indicate that the traditional salary gap between private-practice and academic radiologists may be narrowing.

  • The growth in wRVUs in a time of stagnant or declining salaries after inflation adjustment may confirm the suspicions of both types of radiologists: that they are working harder for less pay. 

The Takeaway

The findings could be a gut punch for private-practice diagnostic radiologists, who are finding that their salary gains aren’t keeping pace with inflation (sound familiar?). They also suggest that academic radiology could offer a refuge from the market and government forces that are reshaping the private sector.

Real-World Stroke AI Implementation

Posted on by Brian Casey

Time is brain. That simple saying encapsulates the urgency in diagnosing and treating stroke, when just a few hours can mean a huge difference in a patient’s recovery. A new study in Clinical Radiology shows the potential for Nicolab’s StrokeViewer AI software to improve stroke diagnosis, but also underscores the challenges of real-world AI implementation.

Early stroke research recommended that patients receive treatment – such as with mechanical thrombectomy – within 6-8 hours of stroke onset. 

  • CT is a favored modality to diagnose patients, and the time element is so crucial that some health networks have implemented mobile stroke units with ambulances outfitted with on-board CT scanners. 

AI is another technology that can help speed time to diagnosis. 

  • AI analysis of CT angiography scans can help identify cases of acute ischemic stroke missed by radiologists, in particular cases of large vessel occlusion, for which one study found a 20% miss rate. 

The U.K.’s National Health Service has been looking closely at AI to provide 24/7 LVO detection and improve accuracy in an era of workforce shortages.

  • StrokeView is a cloud-based AI solution that analyzes non-contrast CT, CT angiography, and CT perfusion scans and notifies clinicians when a suspected LVO is detected. Reports can be viewed via PACS or with a smartphone.  

In the study, NHS researchers shared their experiences with StrokeView, which included difficulties with its initial implementation but ultimately improved performance after tweaks to the software.  

  • For example, researchers encountered what they called “technical failures” in the first phase of implementation, mostly related to issues like different protocol names radiographers used for CTA scans that weren’t recognized by the software. 

Nicolab was notified of the issue, and the company performed training sessions with radiographers. A second implementation took place, and researchers found that across 125 suspected stroke cases  … 

  • Sensitivity was 93% in both phases of the study.
  • Specificity rose from the first to second implementation (91% to 94%).
  • The technical failure rate dropped (25% to 17%).
  • Only two cases of technical failure occurred in the last month of the study.

The Takeaway

The new study is a warts-and-all description of a real-world AI implementation. It shows the potential of AI to improve clinical care for a debilitating condition, but also that success may require additional work on the part of both clinicians and AI developers.

Studies Support Breast Ultrasound for Screening

Posted on by Brian Casey

A pair of new research studies offers guidance on when and where to use ultrasound for breast screening. The publications highlight the important advances being made in one of radiology’s most versatile modalities. 

Ultrasound is used in developed countries for supplementary breast cancer screening in women who may not be suitable for X-ray-based mammography due to issues like dense breast tissue.

  • Ultrasound is also being examined as a primary screening tool in developing regions like China and Africa, where access to mammography may be limited.

But despite growing use, there are still many questions about exactly when and where ultrasound is best employed in a breast screening role – and this week’s studies shed some light. 

First up is a study in Academic Radiology in which researchers compared second-look ultrasound to mammography in women with suspicious lesions found on breast MRI. 

  • Their goal was to find the best clinical path for working up MRI-detected lesions without performing too many unnecessary biopsies. 

In a group of 221 women, second-look ultrasound was largely superior to mammography with… 

  • Higher detection rates for mass lesions (56% vs. 17%).
  • A much higher detection rate for malignant mass lesions > 10 mm (89%).
  • But worse performance with malignant non-mass lesions (22% vs. 38%).

They concluded second-look ultrasound is a great tool for assessment and biopsy of MRI-detected lesions > 10 mm without calcifications. 

  • It’s not so great for suspicious non-mass lesions, which might be better sent to mammography for further workup. 

Breast ultrasound of non-mass lesions was also the focus of a second study, this one published in Radiology. 

  • Non-mass lesions are becoming more frequent as more women with dense breast tissue get supplemental screening, but incidence and malignancy rates are low. 

So how should they be managed? In a study of 993 women with non-mass lesions found on whole-breast handheld screening ultrasound, researchers classified by odds ratios the factors indicating malignancy…

  • Associated calcifications (OR=21.6).
  • Posterior shadowing (OR=6.9).
  • Segmental distribution (OR=6.2).
  • Mixed echogenicity (OR=5.0).
  • Larger size (2.6 vs. 1.9 mm).
  • Negative mammography (2.8% vs. 29%).

The Takeaway

Ultrasound’s value comes from its high prevalence, low cost, and ease of use, but in many ways clinicians are still exploring its optimal role in breast cancer screening. This week’s research studies should help.

CT Lung Screening’s Weak Link

Posted on by Brian Casey

CT lung cancer screening rates in the U.S. remain abysmally low, over a decade after the exam was recommended. Is part of lung screening’s problem its reliance on provider referrals? A new research letter in JAMA Network Open examines this question. 

Unlike breast screening, in which eligible women are able to self-refer themselves for exams, CT lung screening revolves around provider referrals to start the process. 

  • CMS requires a shared decision-making session that results in a written order from a practitioner for a CT lung screening exam in order to pay for screening through Medicare and Medicaid. 

When CMS created the rules in 2015, provider referrals and shared decision-making were seen as ways to get patients involved in their own care by making choices in coordination with their caregivers.

  • But many are starting to see the requirements as a barrier, especially given low CT lung screening rates in the U.S.

In the new article, researchers investigated how easy it would be for an eligible individual to secure a CT lung screening appointment by just calling hospitals – without a provider referral. 

  • They note that one-third of Americans don’t have primary care clinicians, and are often told to call hospitals directly to set up appointments.

So they did just that, placing phone calls to 527 hospitals asking to arrange CT lung screening appointments, finding …

  • 317 calls (60%) failed because the caller did not have a primary care provider’s order.
  • Only 51 hospitals (9.7%) were able to connect callers to any component of a lung cancer screening process. 

The study authors note that the provider referral requirement isn’t the only thing holding CT lung cancer screening back, as even patients with primary care providers aren’t getting screened, and managing nodule follow-up can also be challenging. 

  • But Medicare’s cumbersome reimbursement rules certainly don’t help bring new people into the fold.

The Takeaway

Given CT lung cancer screening’s undisputed life-saving value, there’s no reason to put unnecessary barriers in its way. The provider referral and shared decision-making requirements are lung screening’s weak link to securing greater adoption, and CMS should rescind them to put CT lung cancer screening on the path to greater adoption.

MRI Predicts Cognitive Decline

Posted on by Brian Casey

Early detection of cognitive decline is becoming increasingly important as new therapies become available for conditions like Alzheimer’s disease. A new 20-year study in JAMA Network Open shows that MRI can detect structural brain changes indicating future cognitive decline – years before symptoms occur. 

Longitudinal research has shown that subtle changes in body structure – be they in the heart, brain, or other organs – can predict future disease risk, in some cases decades in advance.

  • That enables the possibility of targeted treatments or behavioral interventions to reduce risk before sick patients experience a cascade of expensive and invasive therapies. 

Mild cognitive impairment is an excellent example. MCI can be a transition to more serious diseases like Alzheimer’s, and previous research has connected it to vascular risk factors that are signs of brain atrophy. 

  • In the current paper, researchers analyzed MRI scans acquired as part of the BIOCARD cohort, a longitudinal study started in 1995 in which cognitively normal participants got baseline brain MRI scans and follow-up exams. 

In a group of 185 BIOCARD participants, researchers tracked how many transitioned to MCI over a mean follow-up period of 20 years, then compared structural brain changes on MRI, finding …

  • 60 participants (32%) progressed to MCI, eight of whom later developed dementia (4.3%).
  • Those with white-matter atrophy on MRI had an 86% higher chance of progression to MCI, the highest rate of any variable studied.
  • Participants with enlargement of the ventricles on MRI had 71% higher risk.
  • Other variables like diabetes and amyloid pathology also had higher risk, but not at the rate of the MRI-detected variables. 

The findings indicate that white-matter volume is closely associated with cognitive function in aging, and that people with higher rates of change are more likely to develop MCI. 

  • The association of diabetes with MCI was not a shock, but researchers said they were surprised there was no association from risk factors like hypertension, dyslipidemia, and smoking.

The Takeaway

The new findings demonstrate the power of MRI to predict pathology years in advance – the question is how and whether to put this knowledge into clinical practice. One could almost see structural brain scans incorporated into whole-body MRI screening exams (if anyone’s listening).

Get every issue of The Imaging Wire, delivered right to your inbox.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Imaging Wire team

You're all set!